Emerging viruses are a major threat to human health. Recent outbreaks have emphasized
the urgent need for new antiviral treatments. For several pathogenic viruses, considerable …

Filoviruses are emerging pathogens and causative agents of viral haemorrhagic fever. Case
fatality rates of filovirus disease outbreaks are among the highest reported for any human …

A systematic screen of FDA-approved drugs was performed to identify compounds with in
vitro antiviral activities against Ebola virus (EBOV). Compounds active (> 50% viral inhibition …

Background The rapid development of effective medical countermeasures against potential
biological threat agents is vital. Repurposing existing drugs that may have unanticipated …

Post translational modification of proteins is a critical requirement that regulates function.
Among the diverse kinds of protein post translational modifications, phosphorylation plays …

Ebola virus (EBOV) causes severe hemorrhagic fever, for which therapeutic options are not
available. Preventing the entry of EBOV into host cells is an attractive antiviral strategy …

The highly lethal filoviruses, Ebola and Marburg cause severe hemorrhagic fever in humans
and non-human primates. To date there are no licensed vaccines or therapeutics to counter …

Activated protein kinase R (PKR) plays a vital role in antiviral defense primarily by inhibiting
protein synthesis and augmenting interferon responses. Many viral proteins have adopted …

The early events in Crimean–Congo hemorrhagic fever virus (CCHFV) have not been
completely characterized. Earlier work indicated that CCHFV likely enters cells by clathrin …

Marburg virus (MARV) and Ebola virus (EBOV), members of the family Filoviridae, represent
a significant challenge to global public health. Currently, no licensed therapies exist to treat …